50 Years of "The Pill": Celebrating a golden anniversary

Journal of Family Planning and Reproductive Health Care

Volumn 36, Issue 4, 2010, Pages 231-238

  Szarewski, Anne ^a   Mansour, Diana ^b   Shulman, Lee P ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b New Croft Centre   (United Kingdom)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Combined oral contraceptives; Venous thromboembolism

Indexed keywords

ANDROGEN RECEPTOR; DESOGESTREL; DIENOGEST; DIENOGEST PLUS ESTRADIOL VALERATE; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ENOVID 10; ESTRADIOL; ESTRADIOL VALERATE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETYNODIOL DIACETATE; GESTODENE; LEVONORGESTREL; LOSEASONIQUE; MESTRANOL; MESTRANOL PLUS NORETYNODREL; NOMEGESTROL ACETATE; NOMEGESTROL ACETATE PLUS ESTRADIOL; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ABORTION; BINDING AFFINITY; BLEEDING; CANCER MORTALITY; CANCER RISK; CLINICAL TRIAL; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FAMILY PLANNING; HEALTH CARE COST; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LIVER METABOLISM; MENSTRUATION; MORBIDITY; MORTALITY; ORAL CONTRACEPTION; OVARY CANCER; OVARY CYCLE; OVULATION; PATIENT SATISFACTION; POSTMARKETING SURVEILLANCE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEXUAL BEHAVIOR; UNPLANNED PREGNANCY; VENOUS THROMBOEMBOLISM;

EID: 78149305213     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118910793048665     Document Type: Review

References (103)

1. United Nations Department of Economic and Social Affairs Population Division. World Contraceptive Use. 2009. http://www.un.org/esa/population/ publications/contraceptive2009/contraceptive2009.htm [Accessed 11 June 2010].
2. World Health Organization (WHO). The World Health Report 2008 - Primary Health Care (Now More Than Ever). 2008. http://www.who.int/whr/2008/en/index. html [Accessed 11 June 2010].
3. Speidel JJ, Grossman RA. Family planning and access to safe and legal abortion are vital to safeguard the environment. Contraception 2007; 76: 415-417.
4. Hardee K. Population, gender, and climate change. BMJ 2009; 339: b4703.
5. Matlin SA, Samuels GMR. Sexual and reproductive health and climate change. Lancet 2009; 374: 949.
6. Alan Guttmacher Institute (AGI). Sharing Responsibility: Women, Society, and Abortion Worldwide. New York, NY: Alan Guttmacher Institute, 1999.
7. Trussell J. The cost of unintended pregnancy in the United States. Contraception 2007; 75: 168-170.
8. Singh S. Hospital admissions resulting from unsafe abortion: estimates from 13 developing countries. Lancet 2006; 368: 1887-1892.
9. Singh S, Wulf D, Hussain R, Bankole A, Sedge G. Abortion Worldwide: A Decade of Uneven Process. 2009. http://www.guttmacher.org/pubs/AWWfullreport.pdf [Accessed 11 June 2010].
10. Grimes DA, Benson J, Singh S, Romero M, Ganatra B, Okonofua FE, et al. Unsafe abortion: the preventable pandemic. Lancet 2006; 368: 1908-1919.
11. UNICEF. Maternal Mortality and Newborn Health. 2009. http://www.unicef. org/health/index-maternalhealth.html [Accessed 17 May 2010].
12. Orr ST, James SA, Reiter JP. Unintended pregnancy and prenatal behaviors among urban, black women in Baltimore, Maryland: the Baltimore preterm birth study. Ann Epidemiol 2008; 18: 545-551.
13. Cheng D, Schwarz EB, Douglas E, Horon I. Unintended pregnancy and associated maternal preconception, prenatal and postpartum behaviors. Contraception 2009; 79: 194-198.
14. SUNY College of Environmental Science and Forestry. Worst Environmental Problem? Overpopulation, Experts Say. 20 April 2009. http://www.sciencedaily. com/releases/2009/04/090418075752.htm [Accessed 17 May 2010].
15. Bryant L, Carver L, Butler CD, Anage A. Climate change and family planning: least-developed countries define the agenda. Bull World Health Organ 2009; 87: 852-857.
16. Meyerson FAB. Population, development and global warming: averting the tragedy of the climate commons. Popul Environ 1998; 19: 443-463. (Pubitemid 28412120)
17. Cohen SA. Hiding in Plain Sight: The Role of Contraception in Preventing HIV. 2008. Guttmacher Policy Review. http://www.guttmacher.org/pubs/gpr/11/1/ gpr110102.html [Accessed 11 June 2010].
18. Fruzzetti F, Bitzer J. Review of clinical experience with estradiol in combined oral contraceptives. Contraception 2010; 81: 8-15.
19. Hoffmann H, Moore C, Zimmermann H, Elger W, Schwarz S, Graser T, et al. Approaches to the replacement of ethinylestradiol by natural 17beta-estradiol in combined oral contraceptives. Exp Toxicol Pathol 1998; 50: 458-464. (Pubitemid 28439499)
20. Nelson AL. Extended-cycle oral contraceptive pills with 10 microg ethinyl estradiol pills in place of placebo pills. Womens Health (Lond Engl) 2007; 3: 529-535.
21. Goldzieher JW, Stanczyk FZ. Oral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestins. Contraception 2008; 78: 4-9.
22. Cerel-Suhl SL, Yeager BF. Update on oral contraceptive pills. Am Fam Physician 1999; 60: 2073-2084.
23. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890.
24. van Hylckama Vlieg A, Heimerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339: b2921.
25. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-1582.
26. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83-88.
27. Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-control study. Int J Epidemiol 1992; 21: 48-52.
28. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457.
29. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133: 32-37.
30. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J (Clin Res Ed) 1986; 292: 526. (Pubitemid 16126103)
31. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002; 65: 187-196. (Pubitemid 34258539)
32. Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception 1999; 60: 321-329.
33. Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 microg versus >20 microg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2008; CD003989.
34. Shapiro S, Dinger J. Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies. J Fam Plann Reprod Health Care 2010; 36: 33-38.
35. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005; 8(Suppl. 1): 3-63.
36. Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003; 349: 1443-1450.
37. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, er al. Classification and pharmacology of progestins. Maturitas 2003; 46(Suppl. 1): S7-S16.
38. Ouzounian S, Verstraete L, Chabbert-Buffet N. Third-generation oral contraceptives: future implications of current use. Expert Rev Obstet Gynecol 2008; 3: 189-201.
39. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2004; 47: 277-283.
40. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002; 9: 6-15. (Pubitemid 34106159)
41. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996; 51: 188-215.
42. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996; 54: 243-251.
43. Oelkers W, Berger V, Bolik A, Bahr V, Hazard B, Beier S, et al. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab 1991; 73: 837-842.
44. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816-1821.
45. Endrikat J, Parke S, Trummer D, Schmidt W, Duijkers I, Klipping C. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception 2008; 78: 218-225.
46. Van Vliet HA, Grimes DA, Heimerhorst FM, Schulz KF. Biphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev 2006; 3: CD002032.
47. Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008; 78: 16-25.
48. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe). Contraception 2007; 75: 16-22. (Pubitemid 44854856)
49. Spona J, Elstein M, Feichtinger W, Sullivan H, Ludicke F, Muller U, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996; 54: 71-77.
50. Kaunitz AM, Burkman RT, Fisher AC, Laguardia KD. Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial. Obstet Gynecol 2009; 114: 1205-1212.
51. Dinger J. The International Active Surveillance Study of Women taking Oral Contraceptives (INAS-OC) study: ACOG 2009: preliminary findings favor 24-day regimen of drospirenone and ethinyl estradiol for contraception. Paper presented at the 57th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG), 57th Annual Clinical Meeting, Chicago, IL, USA, 2-6 May 2009.
52. Wright KP, Johnson JV. Evaluation of extended and continuous use oral contraceptives. Ther Clin Risk Manag 2008; 4: 905-911.
53. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003; 68: 89-96.
54. Anderson FD, Gibbons W, Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 2006; 73: 229-234. (Pubitemid 43202171)
55. Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006; 74: 439-445. (Pubitemid 46037535)
56. Edelman AB, Gallo MF, Jensen JT, Nichols MD, Schulz KF, Grimes DA. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005; CD004695.
57. Coffee AL, Sulak PJ, Kuehl TJ. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 2007; 75: 444-449.
58. Szarewski A. Sisters doing it for themselves. J Fam Plann Reprod Health Care 2009; 35: 71-72.
59. ACOG Practice Bulletin No. 110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol 2010; 115: 206-218.
60. Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ 2010; 340: c927.
61. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol 2004; 190: S5-S22.
62. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2009; CD004425.
63. Reid RL, Mansour D, de Vries C, Verhaeghe J, Boschitsch E, Gompel A, Birkhauser M, Krepelka P, Dulicek P, Iversen OE, Khamoshima M, Vrabic Dezman L, Fruzetti F, Szarewski A, Wilken-Jensen C, Seidman D, Kaaja R, Shapiro S. Oral Contraceptives and Venous Thromboembolism. Consensus Opinion from an International Workshop held in Berlin, Germany in December 2009. J Fam Plann Reprod Health Care 2010; 36: 117-122.
64. Todd J, Lawrenson R, Farmer RD, Williams TJ, Leydon GM. Venous thromboembolic disease and combined oral contraceptives: a re-analysis of the MediPlus database. Hum Reprod 1999; 14: 1500-1505.
65. Suissa S, Spitzer WO, Rainville B, Cusson J, Lewis M, Heinemann L. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod 2000; 15: 817-821. (Pubitemid 30192729)
66. Farmer RD, Todd JC, Lewis MA, MacRae KD, Williams TJ. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study. Contraception 1998; 57: 67-70.
67. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142 475 women-years of observation. Contraception 2007; 75: 344-354.
68. Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56: 141-146. (Pubitemid 27450823)
69. Blumenthal PD, Edelman A. Hormonal contraception. Obstet Gynecol 2008; 112: 670-684.
70. Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 139: 289-296.
71. Pomp ER, Rosendaal FR, Doggen CJ. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol 2008; 83: 97-102.
72. Szarewski A. Choice of contraception. Obstet Gynaecol Repro Med 2009; 19: 323-326.
73. Girolami A, Spiezia L, Girolami B, Zocca N, Luzzatto G. Effect of age on oral contraceptive-induced venous thrombosis. Clin Appl Thromb Hemost 2004; 10: 259-263.
74. Huber JC, Bentz EK, Ott J, Tempfer CB. Non-contraceptive benefits of oral contraceptives. Expert Opin Pharmacother 2008; 9: 2317-2325.
75. La Vecchia C, Bosetti C. Oral contraceptives and neoplasms other than breast and female genital tract. Eur J Cancer Prev 2009; 18: 407-411.
76. Centers for Disease Control and Prevention and National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987; 316: 650-655.
77. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis. Hum Reprod 1997; 12: 1851-1863.
78. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 2006; 95: 385-389.
79. Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet 2003; 362: 185-191. (Pubitemid 36859933)
80. Kabat GC, Miller AB, Rohan TE. Oral contraceptive use, hormone replacement therapy, reproductive history and risk of colorectal cancer in women. Int J Cancer 2008; 122: 643-646.
81. Fernandez E, La Vecchia C, Balducci A, Chatenoud L, Franceschi S, Negri E. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer 2001; 84: 722-727. (Pubitemid 32239011)
82. Levi F, Pasche C, Lucchini F, La Vecchia C. Oral contraceptives and colorectal cancer. Dig Liver Dis 2003; 35: 85-87.
83. Prentice RL, Thomas DB. On the epidemiology of oral contraceptives and disease. Adv Cancer Res 1987; 49: 285-401.
84. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727.
85. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346: 2025-2032.
86. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioners' Oral Contraception Study. BMJ 2007; 335: 651.
87. Milne RL, Knight JA, John EM, Dite GS, Balbuena R, Ziogas A, et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2005; 14: 350-356. (Pubitemid 40270096)
88. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006; 12: 169-178.
89. Ansbacher R. The pharmacokinetics and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol 2001; 184: 255-263. (Pubitemid 32208274)
90. Fugh-Berman A, Bythrow J. Bioidentical hormones for menopausal hormone therapy: variation on a theme. J Gen Intern Med 2007; 22: 1030-1034.
91. Adams C, Cannell S. Women's beliefs about "natural" hormones and natural hormone replacement therapy. Menopause 2001; 8: 433-440.
92. Mansour D. Qlaira®: a 'natural' change of direction. J Fam Plann Reprod Health Care 2009; 35: 139-142.
93. Koetsawang S, Mandlekar AV, Krishna UR, Uurandare VN, Deshpande CK, et al.; for the Task Force on Oral Contraceptives. A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens. Contraception 1980; 21: 445-459.
94. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 beta-estradiol. Fertil Steril 1993; 60: 616-619. (Pubitemid 23298503)
95. Hirvonen E, Allonen H, Anttila M, Kulmala Y, Ranta T, Rautiainen H, et al. Oral contraceptive containing natural estradiol for premenopausal women. Maturitas 1995; 21: 27-32.
96. Mueck AO, Seeger H, Buhling KJ. Why use of dienogest for the first contraceptive pill with estradiol? Gynecol Endocrinol 2009; August 11, 1-5 [Epub ahead of print] DOI: 10.3109/09513590903184167.
97. Sasagawa S, Shimizu Y, Kami H, Takeuchi T, Mita S, Imada K, et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids 2008; 73: 222-231.
98. Dusterberg B, Nishino Y. Pharmacokinetic and pharmacological features of oestradiol valerate. Maturitas 1982; 4: 315-324.
99. Ahrendt HJ, Makalova D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception 2009; 80: 436-444.
100. Chabbert-Buffet N. Synergistic effect of 17β-estradiol and nomegestrol acetate used in a new monophasic oral contraceptive. Paper presented at the 8th Congress of the European Society of Gynecology, Rome, Italy, 10-13 September 2009.
101. Serfaty D, Christin Maitre S, Ochsenbein E, Thomas J-L. Comparison of two regimens of new monophasic oral contraceptive combining 17 beta-estradiol and nomegestrol acetate. Paper presented at the XIX FIGO World Congress of Gynecology and Obstetrics, Cape Town, South Africa, 4-9 October 2009.
102. Catherino WH, Jordan VC. Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J Steroid Biochem Mol Biol 1995; 55: 239-246.
103. Ezan E, Benech H, Bucourt R, Ardouin T, Tchernatinsky C, Thomas JL, et al. Enzyme immunoassay for nomegestrol acetate in human plasma. J Steroid Biochem Mol Biol 1993; 46: 507-514. (Pubitemid 23312322)